摘要 |
The present invention relates to a novel biomarker for predicting sensitivity to an epidermal growth factor receptor (EGFR)-targeting agent, and a use thereof, and more specifically, the present invention provides: a biomarker for predicting sensitivity to the EGFR-targeting agent, the biomarker comprising the Recepteur d'Origine Nantais (RON) gene; a composition for predicting sensitivity to the EGFR-targeting agent, the composition comprising a pharmaceutical preparation for measuring the degree of expression of the gene in the biomarker, or the degree of expression or activity of the protein of the gene; a composition for enhancing sensitivity to the EGFR-targeting agent, the composition comprising, as an active ingredient, an inhibitor inhibiting the expression of the gene, or the expression or activity of the protein of the gene; a kit for predicting sensitivity to the EGFR-targeting agent, the kit comprising the compositions; and a method for predicting sensitivity to the EGFR-targeting agent. According to the present invention, the present invention has an excellent effect of predicting sensitivity to the EGFR-targeting agent for colon cancer, and thus the present invention may be usefully employed for treating colon cancer. |
申请人 |
THE ASAN FOUNDATION |
发明人 |
KIM, TAE WON;JIN, DONG HOON;HONG, SEUNG WOO;MOON, JAI HEE;SHIN, JAE SIK;HWANG, IH YEON;KIM, JEONG HEE;LEE, HA REUM;CHOI, EUN KYOUNG;KIM, SEUNG MI;JUNG, SOO A;HA, SEUNG HEE;LEE, DAE HEE;LEE, EUN YOUNG;LEE, SEUL;LEE, JUNG SHIN;CHOI, EUN KYUNG;LEE, JAE LYUN;HONG, YONG SANG;KIM, KYU PYO;KIM, JEONG EUN;PARK, SEONG JOON;KIM, BONG CHOEL |